Lang et al. demonstrated that cabozantinib in combination with nivolumab significantly increased human T-cell infiltration with increased production of Granzyme B+ (GrB+) and TNFα+IFNγ+ double-producing CD4+ T cells among the tumor-infiltrating leukocytes (TILs), increased PD-L1 expression, along with HLA class I and II on tumor cells and decreased expression of TIM-3 on the CD4+ T cells, an indicative of a less exhausted T-cell pool in the HIS-BRGS mice (Lang et al., 2022). The gene discussed is CD4; the disease is neoplasm.